Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: AIDS. 2019 Apr 1;33(5):867–872. doi: 10.1097/QAD.0000000000002135

Figure 1:

Figure 1:

Box plot showing ELISA-immunoassay urine TFV levels among iPrEx OLE participants who did not acquire HIV; those prior to seroconversion (median 36 weeks); and those at the time of seroconversion